Xiaolin Wan

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models”.

The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-1646

N/A

0.464DataRank · unranked

21 citations

Xiaolin Wan, Jacob S. Roth, David J. Liewehr, Nancy E. Sealover, William J.E. Frye +29 more

Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and Neuroblastoma

Molecular Cancer Therapeutics(2020)10.1158/1535-7163.mct-20-0525

N/A

0DataRank · unranked

20 citations

Xiaolin Wan, Edjay R. Hernandez, Ruibai Luo, Gaelyn C. Lyons, Kelli M. Wilson +17 more

Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma

Oncogene(2022)10.1038/s41388-022-02305-x

N/A

0DataRank · unranked

41 citations

Marielle E. Yohe, Kai Pollard, Angelina V. Vaseva, Ana Calizo, Lindy Zhang +10 more